← Human Trials & Peer-Reviewed Studies
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Plain-language guide to PMID 37294245 (2023): randomized and double-blind clinical study of Semaglutide.
Key Facts
- PMID
- 37294245
- Journal
- JACC. Heart failure
- Year
- 2023
- Study type
- Clinical Study
- Authors
- Kosiborod MN et al. (14 authors)
- DOI
- 10.1016/j.jchf.2023.05.010
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Semaglutide, published as a clinical study.
The aim of this study was to describe the design and baseline characteristics of 2 trials of semaglutide, a glucagon-like peptide-1 receptor agonist, in patients with the obesity HFpEF phenotype: STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF; NCT04788511) and STEP-HFpEF DM (Semaglutide Treatment Effect in People with obesity and HFpEF and type 2 diabetes; NCT04916470).
Why It Was Studied
The majority of patients with heart failure with preserved ejection fraction (HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in HFpEF exist.
Who Took Part
PubMed tags the participants as both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.
Some participants received a placebo instead of Semaglutide, giving a reference point.
Running at several centres spread the Semaglutide study over different clinics and patient groups.
The dual primary endpoints are the 52-week change in the KCCQ-CSS and body weight.
What Was Measured
The subject headings attached to it are Heart Failure, Stroke Volume, Ventricular Function, Left, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Obesity and Diuretics.
Author keywords: 6-minute walking distance, HFpEF, Kansas City Cardiomyopathy Questionnaire, health status, semaglutide and weight loss.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (JACC. Heart failure), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.